Clinical Trial Update: Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity. [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating intratympanic N-acetylcysteine to prevent cisplatin-induced ototoxicity, currently in Phase 1/Phase 2 with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ototoxic Hearing Loss

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Ototoxic Hearing Loss | Phase 1, Phase 2 | Status: UNKNOWN